Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis

Show simple item record

dc.contributor.author Conradie, F
dc.contributor.author Meintjies, G
dc.contributor.author Hughes, J
dc.contributor.author et al
dc.date.accessioned 2015-06-04T13:12:48Z
dc.date.available 2015-06-04T13:12:48Z
dc.date.issued 2014-03
dc.identifier.citation Conradie, F., Meintjies, G., Hughes, J., et al.Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis. SAMJ;104(3):164-166 en_ZA
dc.identifier.uri http://hdl.handle.net/10539/17955
dc.description KM en_ZA
dc.description.abstract While clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme. en_ZA
dc.language.iso en en_ZA
dc.subject Tuberculosis, Multidrug-Resistant en_ZA
dc.subject Bedaquiline en_ZA
dc.title Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search WIReDSpace


Browse

My Account